Cysteine proteases as potential antigens in antiparasitic DNA vaccines

Vaccine

Volumn 29, Issue 34, 2011, Pages 5575-5583

  Jørgensen, Louise von Gersdorff ^a   Buchmann, Kurt ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cysteine proteases; DNA vaccines; Parasites

Indexed keywords

ANTIPARASITIC AGENT; CANDIDA ANTIGEN; CYSTEINE PROTEINASE; DNA VACCINE;

ADAPTIVE IMMUNITY; CESTODE; FLAGELLATE; GENETIC IMMUNIZATION; IMMUNE RESPONSE; LEISHMANIA; MAMMAL; NONHUMAN; PRIORITY JOURNAL; PROTECTION; REVIEW; SCHISTOSOMA; TH2 CELL; VERTEBRATE;

ANIMALS; ANTIPARASITIC AGENTS; CYSTEINE PROTEASES; HOST-PARASITE INTERACTIONS; HUMANS; PARASITIC DISEASES; PARASITIC DISEASES, ANIMAL; TH1-TH2 BALANCE; VACCINATION; VACCINES, DNA;

EID: 79960559864     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.091     Document Type: Review

References (129)

1. Crampton A., Vanniasinkam T. Parasite vaccines: the new generation. Infect Genet Evol 2007, 7(5):664-673.
2. Waitumbi J.N., Anyona S.B., Hunja C.W., Kifude C.M., Polhemus M.E., Walsh D.S., et al. Impact of RTS,S/AS02(A) and RTS. S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial. PLoS One 2009, 4(11):e7849.
3. Kutzler M.A., Weiner D.B. DNA vaccines: ready for prime time?. Nat Rev Genet 2008, 9(10):776-788.
4. Lorenzen N., LaPatra S.E. DNA vaccines for aquacultured fish. Rev Sci Technol 2005, 24(1):201-213.
5. Abdulhaqq S.A., Weiner D.B. DNA vaccines: developing new strategies to enhance immune responses. Immunol Res 2008, 42(1-3):219-232.
6. http://www.drugs.com/vet/apex-ihn-can.html.
7. Garver K.A., LaPatra S.E., Kurath G. Efficacy of an infectious hematopoietic necrosis (IHN) virus DNA vaccine in Chinook Oncorhynchus tshawytscha and sockeye O. nerka salmon. Dis Aquat Organ 2005, 64(1):13-22.
8. Sajid M., McKerrow J.H. Cysteine proteases of parasitic organisms. Mol Biochem Parasitol 2002, 120(1):1-21.
9. Benitez-Hernandez I., Garcia-Zepeda A. Modulation of the inflammatory immune response by parasite proteases. Advances in the immunobiology of parasitic diseases 2007, p. 21-34. L.I. Terrazas (Ed.).
10. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 2006, 5(9):785-799.
11. Juliano M.A., Brooks D.R., Selzer P.M., Pandolfo H.L., Judice W.A., Juliano L., et al. Differences in substrate specificities between cysteine protease CPB isoforms of Leishmania mexicana are mediated by a few amino acid changes. Eur J Biochem 2004, 271(18):3704-3714.
12. Turk D., Guncar G., Podobnik M., Turk B. Revised definition of substrate binding sites of papain-like cysteine proteases. Biol Chem 1998, 379(2):137-147.
13. McKerrow J.H., Caffrey C., Kelly B., Loke P., Sajid M. Proteases in parasitic diseases. Annu Rev Pathol 2006, 1:497-536.
14. Ruszczyk A., Forlenza M., Savelkoul H.F., Wiegertjes G.F. Molecular cloning and functional characterisation of a cathepsin L-like proteinase from the fish kinetoplastid parasite Trypanosoma carassii. Fish Shellfish Immunol 2008, 24(2):205-214.
15. Barrett A.J., Rawlings N.D. Evolutionary lines of cysteine peptidases. Biol Chem 2001, 382(5):727-733.
16. McGrath M.E. The lysosomal cysteine proteases. Annu Rev Biophys Biomol Struct 1999, 28:181-204.
17. Turk V., Turk B., Turk D. Lysosomal cysteine proteases: facts and opportunities. EMBO J 2001, 20(17):4629-4633.
18. Smith A.M., Dowd A.J., Heffernan M., Robertson C.D., Dalton J.P. Fasciola hepatica: a secreted cathepsin L-like proteinase cleaves host immunoglobulin. Int J Parasitol 1993, 23(8):977-983.
19. Kelsall B.L., Ravdin J.I. Degradation of human IgA by Entamoeba histolytica. J Infect Dis 1993, 168(5):1319-1322.
20. Tran V.Q., Herdman D.S., Torian B.E., Reed S.L. The neutral cysteine proteinase of Entamoeba histolytica degrades IgG and prevents its binding. J Infect Dis 1998, 177(2):508-511.
21. Baig S., Damian R.T., Morales-Montor J., Ghaleb A., Baghdadi A., White A.C. Protection from murine cysticercosis by immunization with a parasite cysteine protease. Microbes Infect 2006, 8(12-13):2733-2735.
22. Stewart G.A., Bird C.H., Krska K.D., Colloff M.J., Thompson P.J. A comparative study of allergenic and potentially allergenic enzymes from Dermatophagoides pteronyssinus, D. farinae and Euroglyphus maynei. Exp Appl Acarol 1992, 16(1-2):165-180.
23. Cambra O., Berrens L. Monoclonal antibodies against Dermatophagoides group I allergens as pseudo-cystatins blocking the catalytic site of cysteine proteinases. Immunol Lett 1996, 50(3):173-177.
24. Britton C., Knox D.P., Canto G.J., Urquhart G.M., Kennedy M.W. The secreted and somatic proteinases of the bovine lungworm Dictyocaulus viviparus and their inhibition by antibody from infected and vaccinated animals. Parasitology 1992, 105(Pt 2):325-333.
25. Jousson O., Di Bello D., Donadio E., Felicioli A., Pretti C. Differential expression of cysteine proteases in developmental stages of the parasitic ciliate Ichthyophthirius multifiliis. FEMS Microbiol Lett 2007, 269(1):77-84.
26. Zuo X., Feng S., Woo P.T.K. The in vitro inhibition of proteases from Cryptobia salmositica Katz by a monoclonal antibody (MAb-001) against a glycoprotein on the pathogenic haemoflagellate. J Fish Dis 1997, 20(6):419-426.
27. Woo P.T. Cryptobia (Trypanoplasma) salmositica and salmonid cryptobiosis. J Fish Dis 2003, 26(11-12):627-646.
28. Janeway C. Immunobiology: the immune system in health and disease, vol. xxiii 2005, Garland Science, New York, 823p. 6th ed.
29. Yao Z., Painter S.L., Fanslow W.C., Ulrich D., Macduff B.M., Spriggs M.K., et al. Human IL-17: a novel cytokine derived from T cells. J Immunol 1995, 155(12):5483-5486.
30. Bettelli E., Korn T., Oukka M., Kuchroo V.K. Induction and effector functions of T(H)17 cells. Nature 2008, 453(7198):1051-1057.
31. Hoft D.F., Lynch R.G., Kirchhoff L.V. Kinetic analysis of antigen-specific immune responses in resistant and susceptible mice during infection with Trypanosoma cruzi. J Immunol 1993, 151(12):7038-7047.
32. Humphrey J.S., McCormick T.S., Rowland E.C. Parasite antigen-induced IFN-gamma and IL-4 production by cells from pathopermissive and pathoresistant strains of mice infected with Trypanosoma cruzi. J Parasitol 1997, 83(3):533-536.
33. Kumar S., Tarleton R.L. Antigen-specific Th1 but not Th2 cells provide protection from lethal Trypanosoma cruzi infection in mice. J Immunol 2001, 166(7):4596-4603.
34. Giordanengo L., Guinazu N., Stempin C., Fretes R., Cerban F., Gea S. Cruzipain, a major Trypanosoma cruzi antigen, conditions the host immune response in favor of parasite. Eur J Immunol 2002, 32(4):1003-1011.
35. Schnapp A.R., Eickhoff C.S., Sizemore D., Curtiss R., Hoft D.F. Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice. Infect Immun 2002, 70(9):5065-5074.
36. Heinzel F.P., Schoenhaut D.S., Rerko R.M., Rosser L.E., Gately M.K. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 1993, 177(5):1505-1509.
37. Sypek J.P., Chung C.L., Mayor S.E., Subramanyam J.M., Goldman S.J., Sieburth D.S., et al. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med 1993, 177(6):1797-1802.
38. Afonso L.C., Scharton T.M., Vieira L.Q., Wysocka M., Trinchieri G., Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994, 263(5144):235-237.
39. Souza A.E., Waugh S., Coombs G.H., Mottram J.C. Characterization of a multi-copy gene for a major stage-specific cysteine proteinase of Leishmania mexicana. FEBS Lett 1992, 311(2):124-127.
40. Souza A.E., Bates P.A., Coombs G.H., Mottram J.C. Null mutants for the lmcpa cysteine proteinase gene in Leishmania mexicana. Mol Biochem Parasitol 1994, 63(2):213-220.
41. Mottram J.C., Souza A.E., Hutchison J.E., Carter R., Frame M.J., Coombs G.H. Evidence from disruption of the lmcpb gene array of Leishmania mexicana that cysteine proteinases are virulence factors. Proc Natl Acad Sci U S A 1996, 93(12):6008-6013.
42. Bart G., Frame M.J., Carter R., Coombs G.H., Mottram J.C. Cathepsin B-like cysteine proteinase-deficient mutants of Leishmania mexicana. Mol Biochem Parasitol 1997, 88(1-2):53-61.
43. Mottram J.C., Coombs G.H., Alexander J. Cysteine peptidases as virulence factors of Leishmania. Curr Opin Microbiol 2004, 7(4):375-381.
44. Denise H., McNeil K., Brooks D.R., Alexander J., Coombs G.H., Mottram J.C. Expression of multiple CPB genes encoding cysteine proteases is required for Leishmania mexicana virulence in vivo. Infect Immun 2003, 71(6):3190-3195.
45. Buxbaum L.U., Denise H., Coombs G.H., Alexander J., Mottram J.C., Scott P. Cysteine protease B of Leishmania mexicana inhibits host Th1 responses and protective immunity. J Immunol 2003, 171(7):3711-3717.
46. Alexander J., Coombs G.H., Mottram J.C. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J Immunol 1998, 161(12):6794-6801.
47. Frame M.J., Mottram J.C., Coombs G.H. Analysis of the roles of cysteine proteinases of Leishmania mexicana in the host-parasite interaction. Parasitology 2000, 121(Pt 4):367-377.
48. Saravia N.G., Escorcia B., Osorio Y., Valderrama L., Brooks D., Arteaga L., et al. Pathogenicity and protective immunogenicity of cysteine proteinase-deficient mutants of Leishmania mexicana in non-murine models. Vaccine 2006, 24(19):4247-4259.
49. Pollock K.G., McNeil K.S., Mottram J.C., Lyons R.E., Brewer J.M., Scott P., et al. The Leishmania mexicana cysteine protease, CPB2. 8, induces potent Th2 responses. J Immunol 2003, 170(4):1746-1753.
50. Cameron P., McGachy A., Anderson M., Paul A., Coombs G.H., Mottram J.C., et al. Inhibition of lipopolysaccharide-induced macrophage IL-12 production by Leishmania mexicana amastigotes: the role of cysteine peptidases and the NF-kappaB signaling pathway. J Immunol 2004, 173(5):3297-3304.
51. De Souza Leao S., Lang T., Prina E., Hellio R., Antoine J.C. Intracellular Leishmania amazonensis amastigotes internalize and degrade MHC class II molecules of their host cells. J Cell Sci 1995, 108(Pt 10):3219-3231.
52. Das L., Datta N., Bandyopadhyay S., Das P.K. Successful therapy of lethal murine visceral leishmaniasis with cystatin involves up-regulation of nitric oxide and a favorable T cell response. J Immunol 2001, 166(6):4020-4028.
53. Hoffmann K.F., James S.L., Cheever A.W., Wynn T.A. Studies with double cytokine-deficient mice reveal that highly polarized Th1- and Th2-type cytokine and antibody responses contribute equally to vaccine-induced immunity to Schistosoma mansoni. J Immunol 1999, 163(2):927-938.
54. Wynn T.A., Hoffmann K.F. Defining a schistosomiasis vaccination strategy - is it really Th1 versus Th2?. Parasitol Today 2000, 16(11):497-501.
55. Jankovic D., Aslund L., Oswald I.P., Caspar P., Champion C., Pearce E., et al. Calpain is the target antigen of a Th1 clone that transfers protective immunity against Schistosoma mansoni. J Immunol 1996, 157(2):806-814.
56. Ahmad G., Zhang W., Torben W., Haskins C., Diggs S., Noor Z., et al. Prime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine. Parasitol Res 2009.
57. Rodriguez F., Harkins S., Redwine J.M., de Pereda J.M., Whitton J.L. CD4(+) T cells induced by a DNA vaccine: immunological consequences of epitope-specific lysosomal targeting. J Virol 2001, 75(21):10421-10430.
58. Dumonteil E. DNA vaccines against protozoan parasites: advances and challenges. J Biomed Biotechnol 2007, 2007(6):90520.
59. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., et al. Direct gene transfer into mouse muscle in vivo. Science 1990, 247(4949 Pt 1):1465-1468.
60. Tang D.C., DeVit M., Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature 1992, 356(6365):152-154.
61. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259(5102):1745-1749.
62. Thacker E.L., Holtkamp D.J., Khan A.S., Brown P.A., Draghia-Akli R. Plasmid-mediated growth hormone-releasing hormone efficacy in reducing disease associated with Mycoplasma hyopneumoniae and porcine reproductive and respiratory syndrome virus infection. J Anim Sci 2006, 84(3):733-742.
63. Tüting T., Austyn J., Storkus W.J., Falo L.D.J. The immunology of DNA vaccines. DNA vaccines: methods and protocols. Methods in molecular medicine, vol. 29, xix 2000, Humana Press, Totowa, N.J., 529p. D.B. Lowrie, R.G. Whalen (Eds.).
64. Lorenzen N., Lorenzen E., Einer-Jensen K. Immunity to viral haemorrhagic septicaemia (VHS) following DNA vaccination of rainbow trout at an early life-stage. Fish Shellfish Immunol 2001, 11(7):585-591.
65. Corbeil S., LaPatra S.E., Anderson E.D., Kurath G. Nanogram quantities of a DNA vaccine protect rainbow trout fry against heterologous strains of infectious hematopoietic necrosis virus. Vaccine 2000, 18(25):2817-2824.
66. Lorenzen N., Lorenzen E., Einer-Jensen K., LaPatra S.E. DNA vaccines as a tool for analysing the protective immune response against rhabdoviruses in rainbow trout. Fish Shellfish Immunol 2002, 12(5):439-453.
67. Zapata A., Diez B., Cejalvo T., Gutierrez-de Frias C., Cortes A. Ontogeny of the immune system of fish. Fish Shellfish Immunol 2006, 20(2):126-136.
68. Tadiso T.M., Lie K.K., Hordvik I. Molecular cloning of IgT from Atlantic salmon, and analysis of the relative expression of tau, mu, and delta in different tissues. Vet Immunol Immunopathol 2011, 139(1):17-26.
69. Alvarez-Pellitero P. Fish immunity and parasite infections: from innate immunity to immunoprophylactic prospects. Vet Immunol Immunopathol 2008, 126(3-4):171-198.
70. Ellis A.E. Immunity to bacteria in fish. Fish Shellfish Immunol 1999, 9(4):291-308.
71. Buchmann K., Sigh J., Nielsen C.V., Dalgaard M. Host responses against the fish parasitizing ciliate Ichthyophthirius multifiliis. Vet Parasitol 2001, 100(1-2):105-116.
72. Olsen M.M., Kania P.W., Heinecke R.D., Skjoedt K., Rasmussen K.J., Buchmann K. Cellular and humoral factors involved in the response of rainbow trout gills to Ichthyophthirius multifiliis infections: molecular and immunohistochemical studies. Fish Shellfish Immunol 2011, 30(3):859-869.
73. Jørgensen LvG, Heinecke RD, Skjoedt K, Rasmussen KJ, Buchmann K. Experimental evidence for direct in situ binding of IgM and IgT to invading early trophonts of Ichthyophthirius multifiliis (Fouquet) theronts in the gills of rainbow trout Oncorhynchus mykiss (Walbaum). J Fish Dis; in press.
74. Tonheim T.C., Bogwald J., Dalmo R.A. What happens to the DNA vaccine in fish? A review of current knowledge. Fish Shellfish Immunol 2008, 25(1-2):1-18.
75. Dean D.A. Import of plasmid DNA into the nucleus is sequence specific. Exp Cell Res 1997, 230(2):293-302.
76. Ivory C., Chadee K. DNA vaccines: designing strategies against parasitic infections. Genet Vaccines Ther 2004, 2(1):17.
77. Bojak A., Hammer D., Wolf H., Wagner R. Muscle specific versus ubiquitous expression of Gag based HIV-1 DNA vaccines: a comparative analysis. Vaccine 2002, 20(15):1975-1979.
78. Cazeaux N., Bennasser Y., Vidal P.L., Li Z., Paulin D., Bahraoui E. Comparative study of immune responses induced after immunization with plasmids encoding the HIV-1 Nef protein under the control of the CMV-IE or the muscle-specific desmin promoter. Vaccine 2002, 20(27-28):3322-3331.
79. Hartikka J., Sawdey M., CornefertJensen F., Margalith M., Barnhart K., Nolasco M., et al. An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum Gene Ther 1996, 7(10):1205-1217.
80. Olafsdottir G., Svansson V., Ingvarsson S., Marti E., Torsteinsdottir S. In vitro analysis of expression vectors for DNA vaccination of horses: the effect of a Kozak sequence. Acta Vet Scand 2008, 50:44.
81. Ko H.J., Ko S.Y., Kim Y.J., Lee E.G., Cho S.N., Kang C.Y. Optimization of codon usage enhances the immunogenicity of a DNA vaccine encoding mycobacterial antigen Ag85B. Infect Immun 2005, 73(9):5666-5674.
82. Lin Y., Cheng G., Wang X., Clark T.G. The use of synthetic genes for the expression of ciliate proteins in heterologous systems. Gene 2002, 288(1-2):85-94.
83. Pertmer T.M., Roberts T.R., Haynes J.R. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol 1996, 70(9):6119-6125.
84. Feltquate D.M., Heaney S., Webster R.G., Robinson H.L. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 1997, 158(5):2278-2284.
85. Gurunathan S., Klinman D.M., Seder R.A. DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol 2000, 18:927-974.
86. Li B.W., Rush A., Zhang S.R., Curtis K.C., Weil G.J. Antibody responses to Brugia malayi antigens induced by DNA vaccination. Filaria J 2004, 3(1):1.
87. Herrmann J.E., Chen S.C., Jones D.H., Tinsley-Bown A., Fynan E.F., Greenberg H.B., et al. Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles. Virology 1999, 259(1):148-153.
88. Kaur R., Rauthan M., Vrati S. Immunogenicity in mice of a cationic microparticle-adsorbed plasmid DNA encoding Japanese encephalitis virus envelope protein. Vaccine 2004, 22(21-22):2776-2782.
89. Zhou W.Z., Kaneda Y., Huang S., Morishita R., Hoon D. Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine. Gene Ther 1999, 6(10):1768-1773.
90. Wang J., Hu J.H., Li F.Q., Liu G.Z., Zhu Q.G., Liu J.Y., et al. Strong cellular and humoral immune responses induced by transcutaneous immunization with HBsAg DNA-cationic deformable liposome complex. Exp Dermatol 2007, 16(9):724-729.
91. Wang D., Christopher M.E., Nagata L.P., Zabielski M.A., Li H., Wong J.P., et al. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses. J Clin Virol 2004, 31(Suppl 1):S99-106.
92. Yamano T., Kaneda Y., Huang S., Hiramatsu S.H., Hoon D.S.B. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. Mol Ther 2006, 13(1):194-202.
93. Barouch D.H., Santra S., Schmitz J.E., Kuroda M.J., Fu T.M., Wagner W., et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000, 290(5491):486-492.
94. Kim J.J., Ayyavoo V., Bagarazzi M.L., Chattergoon M.A., Dang K., Wang B., et al. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 1997, 158(2):816-826.
95. Applequist S.E., Rollman E., Wareing M.D., Liden M., Rozell B., Hinkula J., et al. Activation of innate immunity, inflammation, and potentiation of DNA vaccination through mammalian expression of the TLR5 agonist flagellin. J Immunol 2005, 175(6):3882-3891.
96. Grossmann C., Tenbusch M., Nchinda G., Temchura V., Nabi G., Stone G.W., et al. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands. BMC Immunol 2009, 10:43.
97. Chen H.C., Sun B., Tran K.K., Shen H. Effects of particle size on toll-like receptor 9-mediated cytokine profiles. Biomaterials 2011, 32(6):1731-1737.
98. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124(4):783-801.
99. De Rosa S.D., McElrath M.J. T cell responses generated by HIV vaccines in clinical trials. Curr Opin HIV AIDS 2008, 3(3):375-379.
100. Graham B.S., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006, 194(12):1650-1660.
101. Fomsgaard A. HIV-1 DNA vaccines. Immunol Lett 1999, 65(1-2):127-131.
102. Ulmer J.B., Deck R.R., Yawman A., Friedman A., Dewitt C., Martinez D., et al. DNA vaccines for bacteria and viruses. Adv Exp Med Biol 1996, 397:49-53.
103. Ulmer J.B. Influenza DNA vaccines. Vaccine 2002, 20(Suppl. 2):S74-S76.
104. Franco L.H., Wowk P.F., Silva C.L., Trombone A.P., Coelho-Castelo A.A., Oliver C., et al. A DNA vaccine against tuberculosis based on the 65kDa heat-shock protein differentially activates human macrophages and dendritic cells. Genet Vaccines Ther 2008, 6:3.
105. Lowrie D.B. DNA vaccines for therapy of tuberculosis: where are we now?. Vaccine 2006, 24(12):1983-1989.
106. Guo X., Stroup S.E., Houpt E.R. Persistence of Entamoeba histolytica infection in CBA mice owes to intestinal IL-4 production and inhibition of protective IFN-gamma. Mucosal Immunol 2008, 1(2):139-146.
107. Olivos-Garcia A., Tello E., Nequiz-Avendano M., Gonzalez-Canto A., Lopez-Vancell R., Garcia de Leon M.C., et al. Cysteine proteinase activity is required for survival of the parasite in experimental acute amoebic liver abscesses in hamsters. Parasitology 2004, 129(Pt 1):19-25.
108. Martinez M.B., Rodriguez M.A., Garcia-Rivera G., Sanchez T., Hernandez-Pando R., Aguilar D., et al. A pcDNA-Ehcpadh vaccine against Entamoeba histolytica elicits a protective Th1-like response in hamster liver. Vaccine 2009, 27(31):4176-4186.
109. Zadeh-Vakili A., Taheri T., Taslimi Y., Doustdari F., Salmanian A.H., Rafati S. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis. Vaccine 2004, 22(15-16):1930-1940.
110. Rafati S., Salmanian A.H., Taheri T., Vafa M., Fasel N. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine 2001, 19(25-26):3369-3375.
111. Rafati S., Kariminia A., Seyde-Eslami S., Narimani M., Taheri T., Lebbatard M. Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8(+) T lymphocyte activation. Vaccine 2002, 20(19-20):2439-2447.
112. Dumonteil E., Maria Jesus R.S., Javier E.O., Maria del Rosario G.M. DNA vaccines induce partial protection against Leishmania mexicana. Vaccine 2003, 21(17-18):2161-2168.
113. Rafati S., Nakhaee A., Taheri T., Taslimi Y., Darabi H., Eravani D., et al. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 2005, 23(28):3716-3725.
114. Rafati S., Zahedifard F., Nazgouee F. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 2006, 24(12):2169-2175.
115. Tan C.W., Jesudhasan P., Woo P.T. Towards a metalloprotease-DNA vaccine against piscine cryptobiosis caused by Cryptobia salmositica. Parasitol Res 2008, 102(2):265-275.
116. Kumar A., Kumar K., Korde R., Puri S.K., Malhotra P., Singh Chauhan V. Falcipain-1, a Plasmodium falciparum cysteine protease with vaccine potential. Infect Immun 2007, 75(4):2026-2034.
117. Dalton J.P., McGonigle S., Rolph T.P., Andrews S.J. Induction of protective immunity in cattle against infection with Fasciola hepatica by vaccination with cathepsin L proteinases and with hemoglobin. Infect Immun 1996, 64(12):5066-5074.
118. Harmsen M.M., Cornelissen J.B., Buijs H.E., Boersma W.J., Jeurissen S.H., van Milligen F.J. Identification of a novel Fasciola hepatica cathepsin L protease containing protective epitopes within the propeptide. Int J Parasitol 2004, 34(6):675-682.
119. Lee J.S., Kim I.S., Sohn W.M., Lee J., Yong T.S. Vaccination with DNA encoding cysteine proteinase confers protective immune response to rats infected with Clonorchis sinensis. Vaccine 2006, 24(13):2358-2366.
120. Chlichlia K., Bahgat M., Ruppel A., Schirrmacher V. DNA vaccination with asparaginyl endopeptidase (Sm32) from the parasite Schistosoma mansoni: anti-fecundity effect induced in mice. Vaccine 2001, 20(3-4):439-447.
121. Siddiqui A.A., Phillips T., Charest H., Podesta R.B., Quinlin M.L., Pinkston J.R., et al. Induction of protective immunity against Schistosoma mansoni via DNA priming and boosting with the large subunit of calpain (Sm-p80): adjuvant effects of granulocyte-macrophage colony-stimulating factor and interleukin-4. Infect Immun 2003, 71(7):3844-3851.
122. Hota-Mitchell S., Siddiqui A.A., Dekaban G.A., Smith J., Tognon C., Podesta R.B. Protection against Schistosoma mansoni infection with a recombinant baculovirus-expressed subunit of calpain. Vaccine 1997, 15(15):1631-1640.
123. Ahmad G., Torben W., Zhang W., Wyatt M., Siddiqui A.A. Sm-p80-based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni. Parasite Immunol 2009, 31(3):156-161.
124. Ahmad G., Zhang W., Torben W., Damian R.T., Wolf R.F., White G.L., et al. Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model. Vaccine 2009, 27(21):2830-2837.
125. Skuce P.J., Redmond D.L., Liddell S., Stewart E.M., Newlands G.F., Smith W.D., et al. Molecular cloning and characterization of gut-derived cysteine proteinases associated with a host protective extract from Haemonchus contortus. Parasitology 1999, 119(Pt 4):405-412.
126. Muleke C.I., Yan R., Sun Y., Zhao G., Xu L., Li X. Vaccination of goats against Haemonchus contortus with a recombinant cysteine protease. Small Ruminant Res 2007, 73:95-102.
127. Tort L., Balasch J.C., Mackenzie S. Fish immune system. A crossroads between innate and adaptive responses. Inmunología 2003, 22:277-286.
128. Best J.D., Alderton W.K. Zebrafish: an in vivo model for the study of neurological diseases. Neuropsychiatr Dis Treat 2008, 4(3):567-576.
129. Brittijn S.A., Duivesteijn S.J., Belmamoune M., Bertens L.F.M., Bitter W., De Bruijn J.D., et al. Zebrafish development and regeneration: new tools for biomedical research. Int J Dev Biol 2009, 53(5-6):835-850.